I thought we would see the Q reflect some Veneto r

I thought we would see the Q reflect some Veneto revenue. But, we did see that other 8K amendment showing rev numbers so I guess it’s just too early into the acquisition. R and D numbers are basically NIL, with administrative up, and that should or better change to show funding to the pipeline not only the corporate office. We did see the schedule for payments to the NSABP Foundation, and that should kick in.

Merck

“While Merck is not a party to the Clinical Trail Agreement, Merck is expected to provide Keytruda® for the study pursuant to the Clinical Trial Collaboration and Supply Agreement between Antigen and Merck. An initial payment from Generex in the amount of $340,000 is due by December 20, 2018. If the study runs the full anticipated term, Generex will be responsible for an aggregate $2,118,461.”

Generex keeps making this sound like a partnership, although not in their filings. I’m a big fan of AE and I like this combo approach. I talked to Dr Elizabeth Mittendorf, PI of the Phase II from MD Anderson, in correspondence years ago about such a study with Keytruda or a Pd-1. I’m hoping to see this listed formally soon. (Clinicaltrials.gov)

When my accountant talks I zone out so maybe TC has a better read. I think everything looks promising, but as an investor I’d like to see the Veneto legal threat, to their management (and I know Joe can say they didn’t include the specific listed subsidiaries), as I just shown in a previous post how it effected Grainland Pharmacy. That’s all! I’m sure it’s all fine and we’ve seen lots of good things happen and I look forward to more.

What do you think)